2005
DOI: 10.1016/j.ophtha.2004.11.040
|View full text |Cite
|
Sign up to set email alerts
|

14-Year Incidence, Progression, and Visual Morbidity of Age-Related MaculopathyThe Copenhagen City Eye Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

4
99
2
4

Year Published

2007
2007
2021
2021

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 122 publications
(109 citation statements)
references
References 45 publications
4
99
2
4
Order By: Relevance
“…AMD is a chronic, progressive disease with various phenotypic manifestations, different disease stages, and variable rates of progression [3]. Choroidal neovascularization (CNV) and Geographic atrophy (GA) characterize late stages of the disease [4][5][6]. The later occurs in 20% of patients with preexisting clinical hallmarks of this degenerative disease [2,5].…”
Section: Introductionmentioning
confidence: 99%
“…AMD is a chronic, progressive disease with various phenotypic manifestations, different disease stages, and variable rates of progression [3]. Choroidal neovascularization (CNV) and Geographic atrophy (GA) characterize late stages of the disease [4][5][6]. The later occurs in 20% of patients with preexisting clinical hallmarks of this degenerative disease [2,5].…”
Section: Introductionmentioning
confidence: 99%
“…1,2 Central vision can be severely affected if age-related macular degeneration (AMD) develops, characterised in its advanced form by geographic atrophy or choroidal neovascularisation. Drusen are the hallmark feature of ARM, and many studies have reported their prevalence 1,[3][4][5][6][7][8][9][10][11][12][13][14] and/or their natural history in US, 15,16 European, [17][18][19]20 Australian, 11,21,22 and pooled cohorts. 8 Although there is abundant information on drusen prevalence in those aged 50 years and older, only a minority of studies include subjects aged 50 years or less, either as part of cohorts for cross-sectional studies or at baseline in longitudinal studies.…”
Section: Introductionmentioning
confidence: 99%
“…It is well recognized that global population ageing is expected in the next decades, and therefore, the number of patients affected by AMD is expected to increase significantly not only in developed countries, but also in developing countries. Recent estimates point to a projected number of people with AMD in 2020 of 196 million, and of 288 million in 2040 [2, 3]. In this respect, and while prevalence measures the proportion with disease in the population, the incidence adds value because it allows to plan for demand in health care systems and for establishing preventive measures [4].…”
Section: Introductionmentioning
confidence: 99%